Keystone Nano thinks its expertise in nanotechnology can be leveraged to achieve two valuable commercial goals: improving drug delivery and enhancing medical imaging. The company's Molecular Dots are particles that are just 20-30 nanometers wide and resist clumping. As such, they appear to be able to move through the body without disturbing the immune system.
158 Round Hill Road
Boalsburg, PA 16827
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
